Sorrento Therapeutics, Inc. 0L85.L Stock
Sorrento Therapeutics, Inc. Price Chart
Sorrento Therapeutics, Inc. 0L85.L Financial and Trading Overview
Sorrento Therapeutics, Inc. stock price | 0.02 USD |
Previous Close | 0.36 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 3.06 USD |
Volume | 22.4K USD |
Avg. Volume | 10.41K USD |
Market Cap | 437.45K USD |
Beta (5Y Monthly) | 2.099647 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.527 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0L85.L Valuation Measures
Enterprise Value | 313.04M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.007206128 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 5.157 |
Enterprise Value/EBITDA | -0.877 |
Trading Information
Sorrento Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 2.099647 |
52-Week Change | -78.041% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.06 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 0.31 USD |
200-Day Moving Average | 1.2 USD |
0L85.L Share Statistics
Avg. Volume (3 month) | 10.41K USD |
Avg. Daily Volume (10-Days) | 2.93K USD |
Shares Outstanding | 111.3M |
Float | 538.99M |
Short Ratio | N/A |
% Held by Insiders | 0.89% |
% Held by Institutions | 29.37% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -610.55% |
Gross Margin | -285.36% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -35.21% |
Return on Equity (ttm) | -1400.80% |
Income Statement
Revenue (ttm) | 60.71M USD |
Revenue Per Share (ttm) | 0.13 USD |
Quarterly Revenue Growth (yoy) | -11.60% |
Gross Profit (ttm) | -191839000 USD |
EBITDA | -357067008 USD |
Net Income Avi to Common (ttm) | -671644032 USD |
Diluted EPS (ttm) | -1.527 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 50.32M USD |
Total Cash Per Share (mrq) | 0.09 USD |
Total Debt (mrq) | 169.55M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 0.439 |
Book Value Per Share (mrq) | -0.231 |
Cash Flow Statement
Operating Cash Flow (ttm) | -259956000 USD |
Levered Free Cash Flow (ttm) | -122783752 USD |
Profile of Sorrento Therapeutics, Inc.
Country | United Kingdom |
State | CA |
City | San Diego |
Address | 4955 Directors Place |
ZIP | 92121 |
Phone | 858 203 4100 |
Website | https://www.sorrentotherapeutics.com |
Industry | |
Sector(s) | |
Full Time Employees | 949 |
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
Q&A For Sorrento Therapeutics, Inc. Stock
What is a current 0L85.L stock price?
Sorrento Therapeutics, Inc. 0L85.L stock price today per share is 0.02 USD.
How to purchase Sorrento Therapeutics, Inc. stock?
You can buy 0L85.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sorrento Therapeutics, Inc.?
The stock symbol or ticker of Sorrento Therapeutics, Inc. is 0L85.L.
How many shares does Sorrento Therapeutics, Inc. have in circulation?
The max supply of Sorrento Therapeutics, Inc. shares is 1.17M.
What is Sorrento Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Sorrento Therapeutics, Inc. PE Ratio is now.
What was Sorrento Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Sorrento Therapeutics, Inc. EPS is -1.527 USD over the trailing 12 months.